New hope for hairy cell leukemia: targeted combo shows promise

NCT ID NCT06965114

First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 29 times

Summary

This study tests a new combination of drugs (tovorafenib and rituximab) for people with hairy cell leukemia, a rare blood cancer. It includes two parts: one for patients whose cancer returned or didn't respond to prior treatment, and another for newly diagnosed patients comparing the new combo to standard therapy. The goal is to see if the new approach is safer and more effective at wiping out the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • NCI - Center for Cancer Research

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact

    Contact Phone: •••-•••-••••

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Virginia Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.